Repotrectinib

From WikiMD's Food, Medicine & Wellness Encyclopedia

Repotrectinib.svg

Repotrectinib is a tyrosine kinase inhibitor (TKI) that is being developed for the treatment of various types of cancer. It is particularly targeted towards cancers that have specific genetic alterations, such as ROS1, NTRK, and ALK gene fusions. Repotrectinib is designed to overcome resistance to other TKIs and has shown promise in early clinical trials.

Mechanism of Action[edit | edit source]

Repotrectinib works by inhibiting the activity of certain tyrosine kinases, which are enzymes that play a crucial role in the signaling pathways that regulate cell division and survival. By blocking these kinases, repotrectinib can prevent the growth and spread of cancer cells. It is particularly effective against cancers with ROS1, NTRK, and ALK gene fusions, which are known to drive the growth of certain tumors.

Clinical Development[edit | edit source]

Repotrectinib is currently undergoing clinical trials to evaluate its safety and efficacy. Early results have shown that it can be effective in patients who have developed resistance to other TKIs. The drug is being tested in various phases of clinical trials, including Phase I, Phase II, and Phase III studies.

Indications[edit | edit source]

Repotrectinib is being investigated for the treatment of several types of cancer, including:

Side Effects[edit | edit source]

As with other TKIs, repotrectinib can cause a range of side effects. Common side effects include:

Future Directions[edit | edit source]

Research is ongoing to determine the full potential of repotrectinib in treating various cancers. Scientists are also exploring its use in combination with other therapies to enhance its effectiveness and overcome resistance mechanisms.

See Also[edit | edit source]

References[edit | edit source]

External Links[edit | edit source]


Wiki.png

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD


Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.

Contributors: Prab R. Tumpati, MD